On Tuesday, Wolfe Research initiated coverage on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) stock with an Outperform rating and a price target of $40. The firm's outlook is positive ahead of the anticipated market introduction of Madrigal Pharmaceuticals (NASDAQ:MDGL)' treatment, which is expected to have a favorable impact on Akero Therapeutics.
The firm believes that as investors become more confident about the potential market for NASH treatments, Akero's value will be recognized, especially in light of competing treatments showing weaker data.
Wolfe Research's analysis suggests that while Eli Lilly (NYSE:LLY)'s data appears more promising than Novo Nordisk (NYSE:NVO)'s, the overall risk to Akero Therapeutics is considered low. The firm points to both clinical and commercial reasons why Akero's EFX treatment, in combination with GLP-1 therapy, could be successful. The firm's conservative estimates indicate that Akero could reach approximately $3 billion in peak revenue by 2040 for its F2 and F3 NASH treatments.
The analyst's commentary also noted that a potential readout in early 2025 for its F4 treatment could provide modest odds of significant upside. The firm views Akero as a strong candidate for mergers and acquisitions activity due to its promising pipeline and the growing interest in NASH therapies.
Akero Therapeutics' focus on developing treatments for non-alcoholic steatohepatitis (NASH), a liver disease with a significant unmet medical need, positions it within a market that has captured the attention of investors and pharmaceutical companies alike. With Wolfe Research's coverage initiation, Akero Therapeutics gains visibility among investors looking for opportunities in the biopharmaceutical sector.
In other recent news, Akero Therapeutics has seen a flurry of activity. Evercore ISI reduced its price target for Akero Therapeutics to $38.00 from $50.00, citing a reassessment of the company's financial model in light of recent advancements in its phase 3 MASH program.
Despite the adjustment, Evercore maintains an Outperform rating on the stock. Similarly, Canaccord Genuity adjusted its price target for Akero Therapeutics to $56.00 from $59.00, while maintaining a Buy rating. This adjustment was driven by updated projections for fiscal year 2024 operating expenses, largely due to Akero's ongoing and upcoming involvement in three large-scale Phase III clinical studies.
In other developments, Akero Therapeutics announced the appointment of Scott Gangloff as Chief Technology Officer, a move that underscores the company's commitment to advancing its lead product candidate, efruxifermin, through Phase 3 clinical trials for the treatment of metabolic liver disease MASH.
Lastly, BofA Securities reinstated coverage on Akero Therapeutics, assigning the stock a Neutral rating with a price target set at $30.00. The firm noted that while efruxifermin shows promise, there are several challenges ahead, including concerns regarding the drug's safety and tolerability, as well as an intensifying competitive landscape in the NASH treatment market.
InvestingPro Insights
Following Wolfe Research's optimistic take on Akero Therapeutics, InvestingPro data and tips provide further context to investors monitoring the company's financial health and market performance. With a market capitalization of $1.6 billion and a noteworthy 19.77% return over the last week, Akero's recent market activity underscores the positive sentiment echoed by analysts. Additionally, the company's strong cash position relative to debt, as highlighted by one of the InvestingPro Tips, reinforces its financial stability in a volatile market.
Investors should note, however, that Akro's price-to-earnings (P/E) ratio stands at -7.14, reflecting its current lack of profitability, a detail that aligns with analysts' expectations that the company will not be profitable this year. Moreover, the stock's price movement has been in contrast to the general market trend, which could be indicative of its unique position within the biopharmaceutical sector and its potential resilience to broader market shifts.
For those looking to delve deeper into Akero Therapeutics' financials and market prospects, InvestingPro offers additional insights. There are 10 more InvestingPro Tips available, which could guide investment decisions. To explore these further, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a comprehensive toolkit for informed investing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.